Evidence map›Paper›PMID 31440998›Full record

ArticleDigestive diseases and sciences2020

Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.

Michael C Wallace, Kenny Sek, Roslyn J Francis, Shaun Samuelson, John Ferguson, Jonathan Tibballs, Ali Asad, David B Preen, Gerry MacQuillan, George Garas and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds?Transplant international : official journal of the European Society for Organ Transplantation · 2022
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael C WallaceDepartment of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, 6009, WA, Australia. michael.wallace2@health.wa.gov.au.ORCID 0000-0002-2024-9677
Kenny SekDepartment of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Roslyn J FrancisMedical School, University of Western Australia, Nedlands, WA, Australia.
Shaun SamuelsonDepartment of Radiology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
John FergusonDepartment of Radiology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Jonathan TibballsDepartment of Radiology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Ali AsadDepartment of Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
David B PreenSchool of Population and Global Health, University of Western Australia, Nedlands, WA, Australia.
Gerry MacQuillanDepartment of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, 6009, WA, Australia.
George GarasDepartment of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, 6009, WA, Australia.
Leon A AdamsDepartment of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, 6009, WA, Australia.
Gary P JeffreyDepartment of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, 6009, WA, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aims

methodsPatients with early- or intermediate-stage HCC planned for locoregional therapy were prospectively enrolled. Baseline demographic and tumor information was collected and baseline and post-treatment

resultsA total of 29 patients with 39 confirmed HCC lesions were enrolled from a single clinical center. Patients were mostly men (89.7%) with hepatitis C or alcohol-related cirrhosis (65.5%) and early-stage disease (89.7%). Per-patient and per-lesion sensitivity of

conclusionsBaseline and post-treatment

Indexed as

Positron Emission Tomography Computed TomographyRadiopharmaceuticalsAblation TechniquesAgedAged, 80 and overBrachytherapyCarcinoma, HepatocellularChemoembolization, TherapeuticCholineFemaleHepatitis C, ChronicHumansLiver Cirrhosis, AlcoholicLiver NeoplasmsMaleMiddle AgedCholinefluorocholineRadiopharmaceuticals18F-fluorocholineHepatocellular carcinomaPositron emission tomography/computed tomography

Identifiers

PMID31440998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.